HK Stock Market Move | SSY GROUP (02005) rose more than 7% recently, reaching a cooperation agreement with Opterion to introduce the innovative kidney disease drug OPT101.

SSY GROUP (02005) rose by over 7%, reaching 6.93% at the time of writing, at 2.16 Hong Kong dollars, with a turnover of 16.02 million Hong Kong dollars. In recent news, SSY GROUP announced that its wholly-owned subsidiary Shijiazhuang Siyao has signed an intention letter with Opterion Health AG (Opterion) regarding the research, development, production, and commercialization of a new type of non-glucose-based osmotic driver, OPT101 (OPT101) (a type of innovative drug) as an innovative therapy for peritoneal dialysis patients. The Phase I clinical trial data from the European Medicines Agency (EMA) is expected to be obtained in the third quarter of 2026. Therefore, Opterion and Shijiazhuang Siyao are committed to formally signing a cooperation and licensing agreement by the third quarter of 2026. According to the announcement, Opterion will grant Shijiazhuang Siyao exclusive authorization for patents, technical secrets, and platform technology related to OPT101, allowing it to research, develop, produce, and sell authorized products in the People's Republic of China (excluding Hong Kong, Macau, and Taiwan) until 2038. Shijiazhuang Siyao also has priority to obtain authorization for research, development, production, and distribution of OPT101 in Hong Kong, Taiwan, and Russia under the same terms and conditions in the future. Under equal conditions, Shijiazhuang Siyao has the right to prioritize cooperation with Opterion regarding OPT101.